REMINDER: Our user survey closes on Friday, please submit your responses here.
The tide was low and I stood on the sandbank preparing to fish the tide up. You have to be careful as when the tide turns you have to be swift not to get caught out . Rather like PFC, in 2012 £16 + Then dropped to £4 in 2018 and now just 70p. I have always liked this stock especially the old Divi. Now with an increasing order book it has fulfilled my stance on buying from £2 to 70p. and again today. Good luck all you long time holders are time is coming.
25 April 2023
OCI Global and Petrofac announce exclusive partnership for gasification-based green methanol programme
OCI Global, a global leader in ammonia, fertilisers and methanol for transportation and agriculture and Petrofac, an international service provider to the energy industry, announced their partnership to deliver OCI’s programme of gasification-based green methanol projects. The programme will support the production of low-carbon feedstock for OCI’s existing methanol facilities.
OCI will work together with Petrofac, on an exclusive basis, on the design of a standardised gasification process and modular design for the delivery of new waste-fed facilities. Petrofac will deploy its engineering, procurement, and project management expertise to provide continued support to OCI for the delivery of the programme.
Bashir Lebada, CEO OCI Methanol/HyFuels:
“We are delighted to be partnering with Petrofac in the design and delivery of our green methanol ambitions. This is another important step in scaling green methanol and hydrogen technologies and increasing our supply base to service the rapidly increasing demand we see from marine and road fuels. Our partnership with Petrofac will allow us to accelerate delivery of these important green transportation fuels."
John Pearson, Chief Operating Officer, for Petrofac’s New Energy Services business:
“Petrofac is proud to be partnering with OCI to support it in its green methanol production programme. Both our organisations are committed to making the energy transition a reality and we look forward to leveraging our engineering and technical capabilities, alongside our project delivery experience to support this exciting project. Our initial focus will be on fast-tracking the engineering to support OCI’s ambitious programme goals”.
Tremendous contract award today , which should start a recovery in the SP. However PFC has many other buns in the oven. Green hydrogen being one. My friend who has been in Western Oz for some years says the Arrowsmith project will be absolutely huge and PFC will be well placed to take advantage of this new source of energy and contract as well as other projects around the world in this area.
Debt or not , just a glitch (not spike) to me having invested at £4.00 after seeing a drop from £6.00 in 2016 and again at £2.00 as well as losing a very good divi when Covid was rife. I can only see a long awaited rise in SP. May have some ups and down but future now looking bright. Well done PFC .......The Clouds are Lifting
OoooH keeps falling, Friend just phoned to say our share club is folding because of clamp down on Capital gains on shares before tax and Divi allowance falling. Outside ISA just not worth the risk any more. He said he can see sp dropping below £10.50 today. Should have done my home work. Most of my investments covered by ISA's. Budget may spook markets further?? hope not.
Results seemed fine to me. Market over reaction?? catch a falling knife?? Well to offset my losses on stock added today at £10.80. Knowing my luck it may drop further but hope not. Expect MNG will be next after EX divi date is reached.
I think you have mentioned in the following previous messages the reasons. 1. CSBoy stock undervalued. 2. Pman Divi date due. Remember When first spun of from Pru, SP rose to nearly £2.50 and investors then were hoping to get to £3.00 levels. What goes around hopefully comes around. Good luck all !!
Have held AAZ for many years now, the company always seems to understate its achievements. Whilst I hold many different Goldies I must admit That AAZ is the most proactive company when moving forward on future developments as RNS today.
I like the holding in Libero ,the fact that AAZ pays a Divi, produces and sells GEO's and granted extra licences. So hope to see the SP gradually get back to the past highs of £1.75 and beyond. Good luck all investors here.
CASTILLO COPPER LIMITED("Castillo", or the "Company")
Optimising Big One Deposit
Castillo Copper Limited (LSE and ASX: CCZ), a base metal explorer primarily focused on copper across Australia and Zambia, announces that it has completed a strategic asset review which approved several initiatives on how to maximise value from developing the NWQ Copper Project in the Mt Isa copper-belt (complementing work in Broken Hill). Moreover, with the macro-outlook for copper remaining positive and several majors - including Rio Tinto, Glencore and AngloAmerican - active in the Mt Isa region (Figure 1), there is a compelling case to ramp up exploration activities.
HIGHLIGHTS:
· Complementing efforts at the BHA Project's East Zone, the Board has approved plans to assess optimising the Big One Deposit (within the NWQ Copper Project in the Mt Isa copper-belt) via implementing the following:
o Commissioning an independent engineering contractor to conduct a pit optimisation study on the viability of commencing copper mining operations, utilising prospective third-party processors and effective path to market
o Re-formulating optimal plans for a third drilling campaign and companion geophysical surveys to extend known mineralisation beyond the line of lode
· To recap, the Big One Deposit has an inferred Mineral Resource Estimate (MRE) at 2.1Mt @ 1.1% Cu for 21,886t2 copper metal - with best intercepts comprising:
o 40m @ 1.64% Cu from surface incl: 11m @ 4.40% Cu from 24m, 5m @ 7.34% Cu from 28m & 1m @ 16.65% Cu from 29m (303RC)3
o 44m @ 1.19% Cu from surface incl: 14m @ 3.55% Cu from 27m, 3m @ 10.88% Cu from 37m & 1m @ 12.6% Cu from 37m (301RC)3
o 34m @ 1.51% Cu from surface incl: 21m @ 2.25% Cu from surface, 12m @ 3.44% Cu from 3m, 6m @ 4.79% Cu from 3m and 1m @ 9.4% Cu from 9m (B0017)3
· Post upcoming site visits to several targets - including Arya, Valparaisa, Boomerang and Josephine - the Board will rank the exploration potential then present the opportunity to prospective development partners in the Mt Isa region:
o Note, several global mining groups have operations proximal to Castillo's ground including Rio Tinto, Glencore and Anglo American
· Meanwhile, initial metallurgy test-work results for rare earth elements from the BHA Project's East Zone are due back shortly
Ged Hall, Chairman of Castillo Copper, said: "Following a recent strategic asset review, the Board approved an optimization study for the Big One Deposit which should ideally articulate a clear pathway to commence copper mining operations. With exploratory work ramping up at the NWQ Copper and BHA Projects, the Board is increasingly optimistic about the group's prospects for 2023."
Big One Deposit - Optimisation plans
FIGURE 1: NWQ COPPER PROJECT VS MT ISA REGIONAL PEERS
Source: CCZ geology team
Big One Deposit Optimisation
As the only prospect within the NWQ Copper Project that has an inferred MRE
Shield Therapeutics plc
("Shield" or the “Company" or the “Group”)
Full Year Trading Update
Further Reports of Progress on the Commercialization of Accrufer®/Feraccru®
Accrufer® US Total Prescriptions increased to greater than 25,000 in 2022;
Accrufer® Net Product Revenue increased to US$3.5 million in 2022;
Collaborative Sales Agreement signed with Viatris for Accrufer® in the US;
Completion of US$36.7million in financing (gross); and
Fully funded to support operations through to cash flow break-even by end of 2024.
London, UK, 09 February, 2023: Shield Therapeutics plc (LSE: STX), a commercial stage pharmaceutical company focused on the commercialization of Accrufer®/Feraccru® (ferric maltol), a novel oral iron therapy differentiated from other conventional irons by its efficacy, well-tolerated formulation, and broad label, provides the following unaudited trading update for the year ended 31 December 2022, as well as an update on the Company’s progress on the implementation of the collaboration with Viatris Inc (‘Viatris’).
Unaudited Revenue for the year ended 31 December 2022 and Cash position:
Total Revenue of £8.5 million (FY21: £1.5 million) including:
• Net product revenue of £2.8 million from sales of Accrufer® in the US (FY21: £0.1 million)
• Royalty revenue of £1.3 million from product sales in Europe (FY21: £0.9 million)
• Upfront payments of £4.2 million from Viatris and £0.2 million from KYE Pharma on signing of the license agreement for commercialization in Canada (FY21: £0.5 million from Korea Pharma)
Total Financing of c.£30 million (including gross funds received post period):
• US$36.7 million (gross proceeds, comprised of US$21.7 million from placing and open offer, US$5 million upfront payment from Viatris and US$10 million additional borrowings under the amended convertible shareholder loan facility from AOP Health)
• Cash resources sufficient to support operations through to cash flow break-even by end of 2024
US Commercial Update: About 20 million people in the US suffer from anemia including iron deficiency (ID) and iron deficiency with anemia (IDA), reflecting a large, defined yet under-served market. As the first and only FDA approved oral iron to treat iron deficiency with or without anemia, regardless of etiology, Accrufer® has the potential to meet an important unmet medical need for both physicians and patients. Shield has made substantial progress across the following areas:
• Collaborative Sales Agreement with Viatris – Shield signed an exclusive, multi-year agreement with Viatris, Inc, a global healthcare company, in December 2022 to co-commercialize Accrufer®. The collaboration expands the commercial footprint and resources for Accrufer®, as the brand aspires to be the oral iron of choice in the US market. The collaboration will result in a 100-person sales team which will promote Accrufer® to over 12,000 Health Care Professionals that write the majority of oral iron